1419222-75-5

Upstream product

• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 
• 50585-89-2 3-methoxycarbonylpiperidine 
• 1419222-72-2 methyl 1-((3-chloropyrazin-2-yl)methylcarbamoyl)piperidine-3-carboxylate 
• 1419222-73-3 methyl 1-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-3-carboxylate 
• 1419222-74-4 methyl 1-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-3-carboxylate 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 1419222-78-8 1-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)-imidazo[1,5-a]pyrazin-3-yl)piperidine-3-carboxylic acid 
• 1419222-77-7 methyl 1-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)piperidine-3-carboxylate 
• 1419216-30-0 1-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)-N-isopropylpiperidine-3-carboxamide 

Relevant academic research and scientific papers

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.